Pannekoek Anne, Melamed Alexander, Rauh-Hain Jose Alejandro, Ruan Mengyuan, Lipsitz Stuart R, Siguo Li, Molina George
Brigham and Women's Hospital, Department of Surgery, Division of Surgical Oncology, 75 Francis Street, Boston, MA, 02115, USA.
Center for Surgery and Public Health, Brigham and Women's Hospital, Boston, MA, USA.
J Robot Surg. 2025 Jul 9;19(1):366. doi: 10.1007/s11701-025-02549-1.
Colorectal surgeons have been early adopters of MIS. The objective of this study was to evaluate whether use of minimally invasive surgery (MIS) for colorectal cancers (CRC) has had an impact on use of MIS for hepatic, pancreatic, biliary, and gastric cancer (HPB/gastric) at the hospital level. We hypothesized that there is cross-specialty, hospital-level impact between colorectal and HPB/gastric surgeons in their use of MIS. Using the 2010-2019 National Cancer Database, we identified patients with histologically confirmed cancers who underwent curative-intent surgery. The hospital-level use of MIS for CRC and HPB/gastric cancers was standardized by adjusting hospital and patient covariates. Using these adjusted MIS rates as covariates, the yearly-level odds of receiving MIS for HPB/gastric cancers were estimated using logistic regression models. 87,241 and 134,019 patients (median age 65 years) with HPB/gastric cancers and CRC, respectively, were included. The proportion of hospitals performing more than 50% of their cases via MIS for both groups of cancers increased from 1% in 2010 to 27% in 2019. The proportion of hospitals performing more than 10% of their cases via a robotic approach increased from 1 to 33%. The odds of receiving MIS among patients with HPB/gastric cancers were more strongly associated with the level of MIS use for HPB/gastric cancer in the previous year than with MIS use for CRC. Adoption of MIS for HPB/gastric cancers appears to be influenced to a greater degree by intra-specialty factors rather than by cross-specialty use of MIS for CRC.
结直肠外科医生是微创外科(MIS)的早期采用者。本研究的目的是评估在医院层面,对结直肠癌(CRC)使用微创手术(MIS)是否对肝癌、胰腺癌、胆管癌和胃癌(HPB/胃癌)的MIS使用产生了影响。我们假设,在使用MIS方面,结直肠外科医生和HPB/胃癌外科医生之间存在跨专业的医院层面影响。利用2010 - 2019年国家癌症数据库,我们确定了接受根治性手术且组织学确诊癌症的患者。通过调整医院和患者协变量,对CRC和HPB/胃癌的医院层面MIS使用情况进行标准化。以这些调整后的MIS率作为协变量,使用逻辑回归模型估计HPB/胃癌接受MIS的年度层面概率。分别纳入了87241例HPB/胃癌患者和134019例CRC患者(中位年龄65岁)。两组癌症通过MIS进行超过50%病例手术的医院比例从2010年的1%增加到2019年的27%。通过机器人手术方法进行超过10%病例手术的医院比例从1%增加到33%。HPB/胃癌患者接受MIS的概率与上一年HPB/胃癌的MIS使用水平的关联更强,而不是与CRC的MIS使用情况相关。HPB/胃癌采用MIS似乎在更大程度上受专业内因素影响,而非CRC跨专业使用MIS的影响。